Some human brain cancer cells contain a mutated form of...

Some human brain cancer cells contain a mutated form of isocitrate dehydrogenase that has lost its normal activity and instead catalyzes the NADP'-dependent reduction of the carbonyl group of $\alpha$ -ketoglutarate. Draw the structure of the reaction product.

Labs

Want to see this concept in action?

NEW

Explore this concept interactively to see how it behaves as you change inputs.

View Labs

Key Concepts

2-Hydroxyglutarate

The reduction of ?-ketoglutarate by the mutated IDH yields 2-hydroxyglutarate, an oncometabolite. This metabolite can accumulate in cells and interfere with normal cellular functions, including epigenetic regulation, thereby contributing to the development and progression of cancer.

NADP-Dependent Reduction Reaction

This reaction involves the use of NADPH as a cofactor to donate electrons, allowing the reduction of a carbonyl group in a substrate. In the context of the mutated IDH, the reduction of ?-ketoglutarate’s carbonyl results in the formation of a new product rather than proceeding through its normal oxidation pathway.

Isocitrate Dehydrogenase Mutation

Mutations in isocitrate dehydrogenase (IDH) alter the enzyme’s normal catalytic activity, leading to a neomorphic function. Instead of catalyzing the oxidative decarboxylation of isocitrate to ?-ketoglutarate, the mutated enzyme acquires the ability to reduce ?-ketoglutarate, which changes cellular metabolism and can contribute to oncogenesis.

?-Ketoglutarate

?-Ketoglutarate is a key intermediate in the citric acid cycle and plays a critical role in cellular energy metabolism. Its structure features a keto group that is susceptible to reduction under altered enzymatic conditions, which is central to the question at hand.

Please give Ace some feedback